Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.353
EU - Europa 2.606
AS - Asia 1.318
SA - Sud America 20
AF - Africa 7
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.312
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.214
SG - Singapore 606
IE - Irlanda 560
RU - Federazione Russa 522
SE - Svezia 516
IT - Italia 411
HK - Hong Kong 377
DE - Germania 347
CN - Cina 258
CA - Canada 134
GB - Regno Unito 61
UA - Ucraina 47
VN - Vietnam 42
FR - Francia 30
AT - Austria 28
FI - Finlandia 20
RO - Romania 16
BR - Brasile 14
ID - Indonesia 14
NL - Olanda 13
DK - Danimarca 12
IN - India 7
AU - Australia 5
CH - Svizzera 5
MU - Mauritius 5
GR - Grecia 4
IL - Israele 4
JP - Giappone 4
MX - Messico 4
PL - Polonia 4
IR - Iran 3
CL - Cile 2
CZ - Repubblica Ceca 2
ES - Italia 2
NZ - Nuova Zelanda 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BG - Bulgaria 1
EE - Estonia 1
GN - Guinea 1
KR - Corea 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
Totale 10.312
Salva come PNG Salva come JPEG
Città #
Ann Arbor 980
Fairfield 840
Dublin 558
Singapore 511
Woodbridge 412
Ashburn 398
Hong Kong 374
Chandler 368
Wilmington 368
Houston 348
Princeton 308
Frankfurt am Main 291
Cambridge 281
New York 271
Seattle 256
Santa Clara 149
Altamura 140
Lawrence 140
Jacksonville 138
Beijing 111
Ottawa 80
San Diego 79
Milan 73
Andover 46
Toronto 46
Falls Church 31
Shanghai 27
Redmond 24
Vienna 23
Dearborn 22
Dong Ket 20
Nanjing 20
Chicago 19
Norwalk 17
London 16
Helsinki 13
Florence 12
Buffalo 11
Jakarta 11
Moscow 11
Chengdu 10
Wuhan 10
Boardman 9
Fara Gera d'Adda 9
Guangzhou 9
Phoenix 9
Fuzhou 8
Paris 7
Reggio Calabria 7
Rome 7
Shenyang 7
Hefei 6
Kilburn 6
Lachine 6
Los Angeles 6
San Mateo 6
Bonndorf 5
Hounslow 5
Jinan 5
Shenzhen 5
Boulder 4
Bucharest 4
Casoria 4
Catania 4
Cologne 4
Fort Lauderdale 4
Hangzhou 4
Laurel 4
New Bedfont 4
Padova 4
Aiud 3
Bergamo 3
Chennevières-sur-Marne 3
Groningen 3
Hebei 3
Huizen 3
Islington 3
Leawood 3
Modena 3
Nanchang 3
New Delhi 3
Oradea 3
Pavia 3
Pisa 3
Taizhou 3
Tel Aviv 3
Trumbull 3
Udine 3
Amsterdam 2
Arnsberg 2
Baotou 2
Bologna 2
Bolzano 2
Brescia 2
Böblingen 2
Carovigno 2
Chivasso 2
Clearwater 2
Conegliano 2
Delhi 2
Totale 8.103
Salva come PNG Salva come JPEG
Nome #
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 196
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 194
Treatment of venous thromboembolism with tinzaparin in oncological patients 192
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 170
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 161
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 141
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 133
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 129
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 127
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 126
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 123
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 121
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 111
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 108
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 107
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 107
Laboratory haemostasis monitoring in COVID-19 102
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 99
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 98
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 96
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 95
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 95
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 95
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 93
DOACs and “newer” hemophilia therapies in COVID-19: Reply 92
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 91
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 91
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 89
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 89
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 88
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 87
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 87
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 86
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 85
Molecular basis for the relationship between thrombosis and cancer 85
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 85
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 84
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 83
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 83
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 82
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 82
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 82
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 81
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 81
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 81
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 80
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 80
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 79
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 79
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 79
Hemostatic biomarkers in occult cancer and cancer risk prediction 79
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 78
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 77
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 77
Procoagulant mechanisms in tumour cells 76
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 75
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 74
Cancer and venous thromboembolism 73
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 73
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 73
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 72
External validation of the DASH prediction rule: a retrospective cohort study 71
The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting 70
Tromboxane synthetase inhibition results in increased platelet sensivity to prostacyclin. Thrombosis and Haemostasis 69
The mechanisms of cancer-associated thrombosis 69
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 69
Type and dose of heparin in Covid-19: Reply 69
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 68
Acute Promyelocytic Leukemia Coagulopathy. 68
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 68
Clozapine-induced anemia: A case-report 68
Risk of Venous Thromboembolism in Surgical Elderly Patients. 67
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 67
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 67
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 67
Venous thromboembolism in the hematologic malignancies 67
Microparticles in tumor progression 67
Several murine metastatizing tumors possess a cysteine proteinase with cancer procoagulant characteristics 66
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 66
Thrombosis in myeloproliferative neoplasms 65
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 65
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 64
Hemostatic biomarkers in cancer progression 64
Soluble stroma-related biomarkers of pancreatic cancer 64
The Italian START-Register on anticoagulation with focus on atrial fibrillation 64
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 64
Thrombin generation predicts early recurrence in breast cancer patients 64
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 62
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 61
Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells 60
Treatment of thromboembolism in cancer patients 60
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 60
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 59
Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer 58
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 58
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 58
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 56
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 56
V. Plasmaferesi terapeutica 56
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid 56
Totale 8.534
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.508 0 0 0 0 15 27 111 618 314 155 179 89
2020/20212.650 269 278 354 163 137 214 287 296 173 162 187 130
2021/20221.551 160 169 178 92 61 74 93 102 68 97 110 347
2022/20232.055 369 575 190 140 96 407 7 91 97 17 41 25
2023/20241.482 27 52 20 18 227 407 262 46 245 20 5 153
2024/20251.415 306 732 200 167 10 0 0 0 0 0 0 0
Totale 10.988